CytomX Therapeutics, Inc.

CTMX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$14,229-$154$23,525$18,876
Dep. & Amort.$134$347$385$413
Deferred Tax$0$0$0$0
Stock-Based Comp.$1,500$1,431$2,008$1,884
Change in WC$622-$18,088-$47,588-$41,457
Other Non-Cash-$3,575$711$627$376
Operating Cash Flow-$15,548-$15,753-$21,043-$19,908
Investing Activities
PP&E Inv.$127-$27-$119-$80
Net Acquisitions$0$0$0$0
Inv. Purchases$0-$108,833-$19,785-$49,784
Inv. Sales/Matur.$0$32,500$50,500$64,999
Other Inv. Act.$312$0$0$0
Investing Cash Flow$439-$76,360$30,596$15,135
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$93,550$0$2,066
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$253$0$0$183
Financing Cash Flow$253$93,550$0$2,249
Forex Effect$0$0$0$0
Net Chg. in Cash-$14,856$1,437$9,553-$2,524
Supplemental Information
Beg. Cash$50,069$48,632$39,079$41,603
End Cash$35,213$50,069$48,632$39,079
Free Cash Flow-$15,421-$15,780-$21,162-$19,988